Cogent biosciences announces multiple presentations at the 67th annual american society of hematology (ash) meeting

Summit data for bezuclastinib in nonadvsm selected for two oral presentations which will describe its best-in-class potential novel jak2 v617f mutant-selective inhibitor announced as cogent's newest preclinical program; on-track for ind in 2026 waltham, mass. and boulder, colo.
ASH Ratings Summary
ASH Quant Ranking